Ewa Wąsik-Szczepanek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ewa Wąsik-Szczepanek has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
- Dariusz Szczepanek
Neurosurgery and Pediatric Neurosurgery Department in Lublin, Medical University of Lublin, Lublin, Poland
12 shared publications - Marek Hus
Department of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, 20-080 Lublin, Poland
10 shared publications - Agnieszka Bojarska-Junak
Department of Clinical Immunology, Medical University of Lublin, 20-093 Lublin, Poland
9 shared publications - Iwona Hus
Department of Hematology, National Medical Institute of the Ministry of Interior and Administration, Wołoska 137 Str., 02-507 Warsaw, Poland
9 shared publications - Jacek Roliński
Department of Clinical Immunology, Medical University of Lublin, 20-093 Lublin, Poland
9 shared publications Anna Dmoszyńska
7 shared publications
Latest Publications
- Open Access
- 3 September 2025
- Published by Institute of Rural Health in Annals of Agricultural and Environmental Medicine
- Vol. 33 (2) , 234-241
Risk factors affecting the clinical course of COVID-19 in patients with lymphoid malignancies in the Omicron subvariants era – a real-world analysis by the Polish Adult Lukemia Study Group
Introduction and objective: Patients with lymphoid malignancies, were found to have a higher risk of SARS-CoV-2 infection and a severe course of COVID-19. Real-world data (RWD) is presented on the clinical course of COVID-19 in patients with lymphoid malignancies from the centres of the Polish...
- 3 September 2025
- Published by Institute of Rural Health in Annals of Agricultural and Environmental Medicine
- Vol. 33 (2) , 234-241
Open AccessRisk factors affecting the clinical course of COVID-19 in patients with lymphoid malignancies in the Omicron subvariants era – a real-world analysis by the Polish Adult Lukemia Study Group
Introduction and objective: Patients with lymphoid malignancies, were found to have a higher risk of SARS-CoV-2 infection and a severe course of COVID-19. Real-world data (RWD) is presented on the clinical course of COVID-19 in patients with lymphoid malignancies from the centres of the Polish...
- Open Access
Outcome of SARS-CoV-2-Infected Polish Patients with Chronic Lymphocytic Leukemia
Background. The severe acute respiratory syndrome coronavirus (SARS-CoV-2) has become the cause of a worldwide pandemic, and its clinical infection course in patients with hematological malignancies may be severe. Methods. We performed a retrospective study on 188 chronic lymphocytic leukemia patients (CLL) with COVID-19 infection. Results. At the time of infection 51 patients (27.1%) were treated with Bruton tyrosine kinase inhibitor (BTKi), 46 (24.5%) with anti-CD20 antibodies while 37 patients (19.7%) received venetoclax. In total, 111 patients (59.0%) required hospitalization and 50 patients (26.5%) died due to COVID-19. Patients with poor performance status (ECOG >1; p = 0.02), advanced age (>65 years; p = 0.04), low hemoglobin concentration (≤10 g/dl; p = 0.0001), low platelets (p = 0.003), and elevated lactate dehydrogenase level (LDH; p = 0.014) had an increased risk of death due to COVID-19. Neither CLL treatment status (treatment naïve vs. treated) nor the type of CLL-directed treatment had impact on the SARS-CoV-2 related risk of death. The multivariate survival analysis showed that advanced age (p = 0.009) and low platelet count (p = 0.0001) were associated with significantly shorter patients’ overall survival. Conclusions. SARS-CoV-2 infection in CLL patients is associated with poor outcome regardless of administered CLL-directed treatment.
Open AccessOutcome of SARS-CoV-2-Infected Polish Patients with Chronic Lymphocytic Leukemia
Background. The severe acute respiratory syndrome coronavirus (SARS-CoV-2) has become the cause of a worldwide pandemic, and its clinical infection course in patients with hematological malignancies may be severe. Methods. We performed a retrospective study on 188 chronic lymphocytic leukemia patients (CLL) with COVID-19 infection. Results. At the time of infection 51 patients (27.1%) were treated with Bruton tyrosine kinase inhibitor (BTKi), 46 (24.5%) with anti-CD20 antibodies while 37 patients (19.7%) received venetoclax. In total, 111 patients (59.0%) required hospitalization and 50 patients (26.5%) died due to COVID-19. Patients with poor performance status (ECOG >1; p = 0.02), advanced age (>65 years; p = 0.04), low hemoglobin concentration (≤10 g/dl; p = 0.0001), low platelets (p = 0.003), and elevated lactate dehydrogenase level (LDH; p = 0.014) had an increased risk of death due to COVID-19. Neither CLL treatment status (treatment naïve vs. treated) nor the type of CLL-directed treatment had impact on the SARS-CoV-2 related risk of death. The multivariate survival analysis showed that advanced age (p = 0.009) and low platelet count (p = 0.0001) were associated with significantly shorter patients’ overall survival. Conclusions. SARS-CoV-2 infection in CLL patients is associated with poor outcome regardless of administered CLL-directed treatment.
- Open Access
- 16 September 2021
- Published by Institute of Rural Health in Annals of Agricultural and Environmental Medicine
- Vol. 28 (3) , 531-533
An epileptic seizure and haemorrhage into the ventricular system of the brain as the first manifestations of acquired haemophilia A – Case report
Acquired haemophilia (AH) is a suddenly occurring severe blood diathesis that affects both males and females and is caused by autoantibodies which inhibit coagulation factor VIII. The report describes an unusual case of acquired haemophilia in which an epileptic seizure and haemorrhage into the...
- 16 September 2021
- Published by Institute of Rural Health in Annals of Agricultural and Environmental Medicine
- Vol. 28 (3) , 531-533
Open AccessAn epileptic seizure and haemorrhage into the ventricular system of the brain as the first manifestations of acquired haemophilia A – Case report
Acquired haemophilia (AH) is a suddenly occurring severe blood diathesis that affects both males and females and is caused by autoantibodies which inhibit coagulation factor VIII. The report describes an unusual case of acquired haemophilia in which an epileptic seizure and haemorrhage into the...
- Open Access
- 1 January 2021
- Published by Institute of Rural Health in Annals of Agricultural and Environmental Medicine
- Vol. 28 (4) , 733-736
RAEB II type of myelodysplastic syndrome associated with axillary abscesses-Case Report
Myelodysplastic syndromes (MDS) are clonal haematopoetic stem cells disorders, characterized by bone marrow dysplasia, ineffecitive haematopoesis and cytopenias. Due to neutropenia, infections are common. A case is presented of a patient with high-risk myelodysplastic syndrome (MDS) complicated by hidradenitis suppurativa that developed in both axillae. Abscesses required multiple incisions and drainage. After five cycles of treatment with azacitidine, the patient underwent allogenic bone marrow transplantation. Unfortunately, six months after the procedure, the patient lost post-transplant chimerism.Treatment with azacitidine was re-started. After the subsequent ten months, blast transformation was observed. Skin lesions in the course of hidradenitis suppurative persisted and were still considerably active.
- 1 January 2021
- Published by Institute of Rural Health in Annals of Agricultural and Environmental Medicine
- Vol. 28 (4) , 733-736
Open AccessRAEB II type of myelodysplastic syndrome associated with axillary abscesses-Case Report
Myelodysplastic syndromes (MDS) are clonal haematopoetic stem cells disorders, characterized by bone marrow dysplasia, ineffecitive haematopoesis and cytopenias. Due to neutropenia, infections are common. A case is presented of a patient with high-risk myelodysplastic syndrome (MDS) complicated by hidradenitis suppurativa that developed in both axillae. Abscesses required multiple incisions and drainage. After five cycles of treatment with azacitidine, the patient underwent allogenic bone marrow transplantation. Unfortunately, six months after the procedure, the patient lost post-transplant chimerism.Treatment with azacitidine was re-started. After the subsequent ten months, blast transformation was observed. Skin lesions in the course of hidradenitis suppurative persisted and were still considerably active.
- Open Access
- 22 September 2020
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 10 (9) , 299-307
Mantle Cell Lymphoma: Effectiveness of Maintenance Ibrutinib – Case Report
Mantle cell lymphoma is a rare subtype of non- Hodgkin lymphoma with life-threatening course of disease. It mostly affects older adults in their sixth or seventh decade of life with male to female predominance of 3 to 1. It prognosis is very poor and the treatment is demanding. The golden standard therapy for younger, fit patients A 56- years old patient was admitted to the Department of Hematooncology and Bone Marrow Transplantation with clinical symptoms such as heavy night sweats, generalized enlargement of lymph nodes, massive weight loss, dyspnea and fatigue. Initial physical examination and imaging showed enormous hepatosplenomegaly, mass in the lungs and fluid in the pleural cavity.The patients underwent chemioimmunotherapy consolidated with an autologous stem cell transplant. To date, the patient is on maintenance treatment with ibrutinib.
- 22 September 2020
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 10 (9) , 299-307
Open AccessMantle Cell Lymphoma: Effectiveness of Maintenance Ibrutinib – Case Report
Mantle cell lymphoma is a rare subtype of non- Hodgkin lymphoma with life-threatening course of disease. It mostly affects older adults in their sixth or seventh decade of life with male to female predominance of 3 to 1. It prognosis is very poor and the treatment is demanding. The golden standard therapy for younger, fit patients A 56- years old patient was admitted to the Department of Hematooncology and Bone Marrow Transplantation with clinical symptoms such as heavy night sweats, generalized enlargement of lymph nodes, massive weight loss, dyspnea and fatigue. Initial physical examination and imaging showed enormous hepatosplenomegaly, mass in the lungs and fluid in the pleural cavity.The patients underwent chemioimmunotherapy consolidated with an autologous stem cell transplant. To date, the patient is on maintenance treatment with ibrutinib.
- Open Access
- 17 March 2020
- Published by Institute of Rural Health in Annals of Agricultural and Environmental Medicine
- Vol. 27 (1) , 160-164
Rare case of Richter’s syndrome localization in liver and thyroid of a patient with a chronic lymphocytic leukemia (CLL) – Case report and literature
Richter’s syndrome (RS) is a rare complication in which chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) transforms into a more aggressive type of lymphoma – diffuse large B cell lymphoma (DLBCL), or Hodgkin’s lymphoma (HL). The review describes the clinical case of a...
- 17 March 2020
- Published by Institute of Rural Health in Annals of Agricultural and Environmental Medicine
- Vol. 27 (1) , 160-164
Open AccessRare case of Richter’s syndrome localization in liver and thyroid of a patient with a chronic lymphocytic leukemia (CLL) – Case report and literature
Richter’s syndrome (RS) is a rare complication in which chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) transforms into a more aggressive type of lymphoma – diffuse large B cell lymphoma (DLBCL), or Hodgkin’s lymphoma (HL). The review describes the clinical case of a...
- Open Access
- 29 August 2018
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 27 (12) , 1683-1689
Richter syndrome: A rare complication of chronic lymphocytic leukemia or small lymphocytic lymphoma
Richter's syndrome (RS) is a rare complication with an unfavorable prognosis, in which chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) transform into a more aggressive type of lymphoma, most commonly into diffuse large B cell lymphoma (DLBCL) or less often into Hodgkin's lymphoma (HL). The objective of this research paper was to present a retrospective analysis of patients with CLL/SLL whose disease transformed into RS. The study included 217 patients (100 women and 107 men) with CLL/SLL diagnosed in the years 2006-2015 at the Department of Hematooncology and Bone Marrow Transplantation of the Medical University of Lublin, which transformed into RS. We analyzed clinical, laboratory, immunophenotypic (ZAP-70 and CD38 expression), histopathological, and genetic data (del(17p), del(11q)), which was collected at the time of CLL/SLL diagnosis, and some which was collected at the time of transformation. Richter's syndrome was diagnosed in 4.6% of all CLL and SLL patients. The group of patients with RS consisted of 9 patients with primary CLL and 1 patient with a diagnosis of SLL (8 patients with transformation into DLBCL and 2 patients with transformation into HL). Leukemic lymphocytes showed evidence of peripheral blood lymphocyte membrane expression of ZAP70+/CD38+ (1 patient), of ZAP-70+/CD38- (3 patients), of ZAP-70-/CD38- (1 patient), and of ZAP-70-/CD38+ (5 patients). The deletion of 11q (del(11q)) was documented in 2 patients. In 4 cases, the location of RS was extremely rare (the thyroid gland, liver, skin, bladder, and central nervous system). Richter's syndrome is a rare, but probable complication of CLL/SLL with an unfavorable prognosis, and it should be taken into account at every stage of the disease, particularly when the course of the disease is aggressive.
- 29 August 2018
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 27 (12) , 1683-1689
Open AccessRichter syndrome: A rare complication of chronic lymphocytic leukemia or small lymphocytic lymphoma
Richter's syndrome (RS) is a rare complication with an unfavorable prognosis, in which chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) transform into a more aggressive type of lymphoma, most commonly into diffuse large B cell lymphoma (DLBCL) or less often into Hodgkin's lymphoma (HL). The objective of this research paper was to present a retrospective analysis of patients with CLL/SLL whose disease transformed into RS. The study included 217 patients (100 women and 107 men) with CLL/SLL diagnosed in the years 2006-2015 at the Department of Hematooncology and Bone Marrow Transplantation of the Medical University of Lublin, which transformed into RS. We analyzed clinical, laboratory, immunophenotypic (ZAP-70 and CD38 expression), histopathological, and genetic data (del(17p), del(11q)), which was collected at the time of CLL/SLL diagnosis, and some which was collected at the time of transformation. Richter's syndrome was diagnosed in 4.6% of all CLL and SLL patients. The group of patients with RS consisted of 9 patients with primary CLL and 1 patient with a diagnosis of SLL (8 patients with transformation into DLBCL and 2 patients with transformation into HL). Leukemic lymphocytes showed evidence of peripheral blood lymphocyte membrane expression of ZAP70+/CD38+ (1 patient), of ZAP-70+/CD38- (3 patients), of ZAP-70-/CD38- (1 patient), and of ZAP-70-/CD38+ (5 patients). The deletion of 11q (del(11q)) was documented in 2 patients. In 4 cases, the location of RS was extremely rare (the thyroid gland, liver, skin, bladder, and central nervous system). Richter's syndrome is a rare, but probable complication of CLL/SLL with an unfavorable prognosis, and it should be taken into account at every stage of the disease, particularly when the course of the disease is aggressive.
- 1 May 2018
- Published by VM Media Group sp. z o.o in Neurologia i Neurochirurgia Polska
- Vol. 52 (3) , 410-414
Intraventricular treatment of secondary central nervous system lymphoma – Case study and literature overview
Secondary nervous system lymphoma (SCNSL) is a rare extranodal form of non-Hodgkin lymphoma (NHL). This applies to a particular form of lymphoma that does not originally derive from the central nervous system (CNS); it can be both an isolated form of relapse or a systemic part of disease progression. Due to poor prognosis and a lack of established algorithms of therapeutic procedures, it is a big challenge for physicians from many specializations. In our study, we present an interesting case of a patient with a relapsed form of SCNSL for whom a unique form of treatment was used - intraventricular administration of rituximab and methotrexate.
- 1 May 2018
- Published by VM Media Group sp. z o.o in Neurologia i Neurochirurgia Polska
- Vol. 52 (3) , 410-414
Intraventricular treatment of secondary central nervous system lymphoma – Case study and literature overview
Secondary nervous system lymphoma (SCNSL) is a rare extranodal form of non-Hodgkin lymphoma (NHL). This applies to a particular form of lymphoma that does not originally derive from the central nervous system (CNS); it can be both an isolated form of relapse or a systemic part of disease progression. Due to poor prognosis and a lack of established algorithms of therapeutic procedures, it is a big challenge for physicians from many specializations. In our study, we present an interesting case of a patient with a relapsed form of SCNSL for whom a unique form of treatment was used - intraventricular administration of rituximab and methotrexate.
- Open Access
- 14 March 2018
- Published by Institute of Rural Health in Annals of Agricultural and Environmental Medicine
- Vol. 25 (1) , 56-59
Assessment of the efficacy of ofatumumab in patients with chronic lymphocytic leukaemia treated in the Department of Haematooncology and Bone Marrow Transplantation of the Medical University in Lublin – Prelimary results
[b] Abstract Introductio[/b]n. Despite significant recent advances in the treatment of chronic lymphocytic leukaemia (CLL), most cases of the disease are still incurable. Treatment with monoclonal antibodies, such as ofatumumab, is one of the new therapeutic options. Objective. Retrospective...
- 14 March 2018
- Published by Institute of Rural Health in Annals of Agricultural and Environmental Medicine
- Vol. 25 (1) , 56-59
Open AccessAssessment of the efficacy of ofatumumab in patients with chronic lymphocytic leukaemia treated in the Department of Haematooncology and Bone Marrow Transplantation of the Medical University in Lublin – Prelimary results
[b] Abstract Introductio[/b]n. Despite significant recent advances in the treatment of chronic lymphocytic leukaemia (CLL), most cases of the disease are still incurable. Treatment with monoclonal antibodies, such as ofatumumab, is one of the new therapeutic options. Objective. Retrospective...
- 1 March 2018
- Published by VM Media Group sp. z o.o in Neurologia i Neurochirurgia Polska
- Vol. 52 (2) , 228-234
Central nervous involvement by chronic lymphocytic leukaemia
Inclusion of the central nervous system (CNS) in the course of chronic lymphocytic leukaemia (CLL) is rare. At the moment no risk factors or proven treatment methods are known. The disease is described both in its early phase and during its acceleration period, thus it has been suggested that there might be independent mechanisms influencing the development of this condition. As there are no unified diagnostic procedure algorithms each patient needs to be assessed individually. CLL can manifest mostly in elderly people, for whom a possibility of development of neurological disorders with their aetiology different from leukaemia, should also be taken into consideration. The thesis presents a group of seven patients with CLL with CNS infiltration. Patients with prolymphocytic leukaemia, Richter's transformation and the original location of leukemic infiltration within the eye socket constitute an especially interesting case. (C) 2017 Published by Elsevier Sp. z o. o. on behalf of Polish Neurological Society.
- 1 March 2018
- Published by VM Media Group sp. z o.o in Neurologia i Neurochirurgia Polska
- Vol. 52 (2) , 228-234
Central nervous involvement by chronic lymphocytic leukaemia
Inclusion of the central nervous system (CNS) in the course of chronic lymphocytic leukaemia (CLL) is rare. At the moment no risk factors or proven treatment methods are known. The disease is described both in its early phase and during its acceleration period, thus it has been suggested that there might be independent mechanisms influencing the development of this condition. As there are no unified diagnostic procedure algorithms each patient needs to be assessed individually. CLL can manifest mostly in elderly people, for whom a possibility of development of neurological disorders with their aetiology different from leukaemia, should also be taken into consideration. The thesis presents a group of seven patients with CLL with CNS infiltration. Patients with prolymphocytic leukaemia, Richter's transformation and the original location of leukemic infiltration within the eye socket constitute an especially interesting case. (C) 2017 Published by Elsevier Sp. z o. o. on behalf of Polish Neurological Society.